Ken Kobayashi

Summary

Country: Japan

Publications

  1. ncbi Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer
    K Takeda
    Department of Pulmonary Medicine, Osaka City General Hospital, Japan
    Cancer Chemother Pharmacol 48:104-8. 2001
  2. ncbi Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer
    Koji Takeda
    Department of Clinical Oncology and Pulmonary Medicine, Osaka City General Hospital, 2 13 22 Miyakojimahondohri, Miyakojima ku, 534 0021, Osaka, Japan
    Lung Cancer 38:303-8. 2002
  3. ncbi Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study
    Koji Takeda
    Department of Clinical Oncology, Osaka City General Hospital, 2 13 22, Miyakojimahondohri, Osaka 5340021, Japan
    Invest New Drugs 25:377-83. 2007
  4. ncbi Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
    K Takeda
    Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan
    Ann Oncol 20:835-41. 2009
  5. ncbi Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (W
    Koji Takeda
    2 13 22 Miyakojimahondohri, Miyakojima ku, Osaka 534 0021, Japan
    J Clin Oncol 28:753-60. 2010
  6. ncbi A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706
    Koji Takeda
    Department of Clinical Oncology, Osaka City General Hospital, 2 13 22 Miyakojima Hondori, Miyakojima ku, Osaka 534 0021, Japan
    Jpn J Clin Oncol 41:25-31. 2011
  7. ncbi The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors
    Haruko Daga
    Osaka City General Hospital, 2 13 22 Miyakojimahondori, Miyakojima ku, Osaka 534 0021, Japan
    Jpn J Clin Oncol 41:1067-73. 2011

Collaborators

Detail Information

Publications7

  1. ncbi Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer
    K Takeda
    Department of Pulmonary Medicine, Osaka City General Hospital, Japan
    Cancer Chemother Pharmacol 48:104-8. 2001
    ..5 months and 35.3%, respectively. The maximum tolerated dose of irinotecan with this regimen was 60 mg/m2, while 50 mg/m2 can be recommended for future use. Further studies of this combination in advanced NSCLC are warranted...
  2. ncbi Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer
    Koji Takeda
    Department of Clinical Oncology and Pulmonary Medicine, Osaka City General Hospital, 2 13 22 Miyakojimahondohri, Miyakojima ku, 534 0021, Osaka, Japan
    Lung Cancer 38:303-8. 2002
    ..86 and 0.43, respectively. It seemed that CPT-11 and CBDCA was more toxic regimen than CPT-11 and CDDP in advanced NSCLC. The relatively disappointing response rate could be related with low dose intensity of CPT-11...
  3. ncbi Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study
    Koji Takeda
    Department of Clinical Oncology, Osaka City General Hospital, 2 13 22, Miyakojimahondohri, Osaka 5340021, Japan
    Invest New Drugs 25:377-83. 2007
    ..We conducted a multicenter phase II study of amrubicin, a novel 9-aminoanthracycline, to evaluate its efficacy and safety in patients with non-small-cell lung cancer (NSCLC)...
  4. ncbi Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
    K Takeda
    Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan
    Ann Oncol 20:835-41. 2009
    ..This trial evaluated whether a combination of docetaxel and gemcitabine provides better survival than docetaxel alone in patients with previously treated non-small-cell lung cancer (NSCLC)...
  5. ncbi Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (W
    Koji Takeda
    2 13 22 Miyakojimahondohri, Miyakojima ku, Osaka 534 0021, Japan
    J Clin Oncol 28:753-60. 2010
    ..The exploratory subset analyses demonstrate a possible survival prolongation for sequential therapy of gefitinib, especially for patients with adenocarcinoma...
  6. ncbi A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706
    Koji Takeda
    Department of Clinical Oncology, Osaka City General Hospital, 2 13 22 Miyakojima Hondori, Miyakojima ku, Osaka 534 0021, Japan
    Jpn J Clin Oncol 41:25-31. 2011
    ..It is important to identify optimal regimens of cisplatin-based, third-generation chemotherapy and thoracic radiotherapy for patients with unresectable, Stage III, non-small cell lung cancer...
  7. ncbi The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors
    Haruko Daga
    Osaka City General Hospital, 2 13 22 Miyakojimahondori, Miyakojima ku, Osaka 534 0021, Japan
    Jpn J Clin Oncol 41:1067-73. 2011
    ....